Clinical Report: Laser First: Rethinking Glaucoma Therapy
Overview
Recent advancements in glaucoma therapy emphasize selective laser trabeculoplasty (SLT) as a potential first-line treatment, challenging the long-standing reliance on topical medications. The LiGHT trial demonstrates that SLT can provide effective intraocular pressure control with fewer complications and better long-term outcomes compared to traditional medical therapy.
Background
Glaucoma management has traditionally relied on topical medications, which, despite their effectiveness, are associated with high rates of nonadherence and ocular surface disease. The emergence of SLT and other innovative therapies presents an opportunity to improve patient outcomes and quality of life. Understanding these new treatment paradigms is essential for optimizing care for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).
Data Highlights
| Study | Findings |
|---|---|
| LiGHT Trial | SLT group had lower risks of glaucoma progression and surgery needs compared to medication group over 6 years. |
| SLT Success Rate | 56% of SLT patients maintained IOP control without further interventions at 6 years. |
| Medication-Free Rate | 70% of SLT patients remained drop-free with repeat treatments included. |
| Ocular Side Effects | Significantly more common with medical therapy than SLT. |
Key Findings
- SLT offers a drop-free lifetime of glaucoma care for many patients.
- Over 6 years, SLT showed lower rates of glaucoma progression and surgical interventions compared to traditional medications.
- 56% of patients treated with SLT maintained well-controlled IOP without additional treatments.
- SLT has a favorable safety profile, with no sight-threatening complications reported in the LiGHT trial.
- Adherence to medication is a significant challenge, which SLT addresses by providing consistent IOP control.
Clinical Implications
Clinicians should consider SLT as a first-line treatment option for newly diagnosed POAG and OHT patients, given its efficacy and safety profile. This shift may lead to improved patient adherence and quality of life, reducing the burden of chronic topical therapy.
Conclusion
The findings from the LiGHT trial support a paradigm shift in glaucoma management, positioning SLT as a viable first-line therapy that can enhance patient outcomes and reduce reliance on topical medications.
References
- Glaucoma Physician, The Latest in Laser Treatment for Glaucoma, 2024 -- Promising new options could help patients get away from reliance on drops.
- Glaucoma Physician, Combined Electroretinography and Selective Laser Trabeculoplasty for Glaucoma, 2018 -- Team glaucoma has acquired new players.
- Ophthalmology Management, SLT earns a place as first-line therapy, 2020 -- Selective laser trabeculoplasty may supersede drops in glaucoma treatment.
- European Glaucoma Society, 2026 -- Guidelines on first-line selective laser trabeculoplasty.
- Ophthalmology Management, Laser treatment vs drops, 2021 -- A comparative analysis of treatment options.
- European Glaucoma Society -- Six-Year Rate of Visual Field Progression in the LiGHT Trial
- Selective Laser Trabeculoplasty Compared to Medication for Open-Angle Glaucoma Patients: A Systematic Review and Meta-Analysis
- European Glaucoma Society
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
